Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16120099 | 0.90 | NOTUM (0.38) | RORCHTR3ASCARB1CNR2 | |
| SCHEMBL17461831 | 0.89 | MAP2K2 (0.37) | JAK2JAK1TYK2JAK3PARP1 | |
| SCHEMBL17461861 | 0.86 | HTR3A (0.39) | RORCHTR3ASCARB1KDM4E | |
| SCHEMBL16120079 | 0.81 | NPC1 (0.45) | NPC1CNR2 | |
| SCHEMBL17461845 | 0.79 | NPC1 (0.43) | JAK2JAK1TYK2JAK3NPC1 | |
| SCHEMBL16099363 | 0.77 | PTGER4 (0.46) | RORCSCARB1CNR2 | |
| SCHEMBL7054203 | 0.74 | ADRA1D (0.49) | JAK2JAK1JAK3RORCADRA1D | |
| SCHEMBL16120031 | 0.72 | CHEK1 (0.34) | PARP1NPC1KDM4E | |
| SCHEMBL16093815 | 0.69 | NPC1 (0.54) | RORCNPC1CNR2KDM4E | |
| SCHEMBL27506447 | 0.69 | ADRA1D (0.44) | JAK2JAK1JAK3ADRA1DMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014153043-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | AR, KLK3, BRDT | JAK2 1075/4885JAK1 1656/4885TYK2 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.